The New T Cell Subset Opens a New Realm for Tumor Immunotherapy

Zhu, Huanjin; Zeng, Chong; Wang, Weidong

doi:10.1177/09636897221138037

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first is performing extra genetic modifications in addition to the introduction of CAR transgenes on donor αβ T cells. Another is selecting alternative cell sources or subpopulations, such as induced pluripotent stem cells (iPSCs), umbilical cord blood (UCB) cells, γδ T cells, memory T cell subpopulations, virus-specific T cells 129 (VST), and so on 132 .…”

Section: Improve the Efficiency Of The Gene Transfer Methodsmentioning

confidence: 99%

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

Han,

Zhang,

Zheng

et al. 2024

Cell Transplant

View full text Add to dashboard Cite

Immune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection.

show abstract

Section: Improve the Efficiency Of The Gene Transfer Methodsmentioning

confidence: 99%